Pharma BD Deal Intelligence
Sanofi's $1.9 billion cash tender for Chattem was a straightforward entry play into the US OTC consumer-healthcare market, paying a 34% premium ($93.50/share) for an established brand portfolio. It gave Sanofi immediate scale in consumer health, though the deal added no new molecules or pipeline assets to the franchise.
Sanofi acquired Chattem for ~$1.9B for US consumer healthcare.
Sanofi-Aventis completes acquisition of Chattem consumer healthcare company.
Sanofi-aventis successfully completes acquisition of Chattem Inc for $93.50 per share approximately $1.9 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi-aventis acquired Chattem in an all-cash tender offer at $93.50/share (~$1.9B, a 34% premium), entering the US OTC/consumer-healthcare market; announced December 21, 2009 and completed Q1 2010.
Sanofi completed $1.9B acquisition of Chattem, gaining consumer healthcare brands including Gold Bond, Icy Hot, and other OTC products.
Sanofi SA closes acquisition/merger of Chattem Inc. for $1.9B, establishing strategic position and initiating integration.
Chattem brands fully integrated into Sanofi Consumer Healthcare, contributing steady revenue from established US OTC brands.
Strategic Fit: 72/100 | Financial Return: 68/100 | Pipeline Outcome: 55/100 | Integration: 70/100 | Deal Difficulty: 35/100. Partially Achieved overall outcome.
Chattem provided diversified US consumer healthcare portfolio. Brands generate predictable revenue but limited growth upside. Adequate fit.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Chattem Inc. (this deal) | 2009 | $1.9B | 64 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2009 deals · Sanofi SA deals